Issues

New therapeutic advances are needed for acute myeloid leukemia (AML) given low rates of cure using standard therapies. Two studies by Kornauth, Pemovska, Vladimer, and colleagues (page 372) and Malani and colleagues (page 388) deployed drug sensitivity testing to uncover efficacious individualized therapy for patients with hematologic malignancies, including AML. Kornauth, Pemovska, Vladimer, and colleagues established that functional drug profiling on a single-cell level improved response in patients with relapsed or refractory hematologic malignancies. Malani and colleagues found, using multiomic profiling of a functional and molecular tumor board in AML, potential actionable drugs for nearly all of the involved patients as well as an increased response rate upon clinical implementation of the individually tailored recommendations. For more information, see the corresponding articles at the page numbers listed above.